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Abstract
The purpose of our study was to determine the value of different hybrid imaging combina-
tions for the detection of focal and diffuse bone marrow infiltration in lymphoma. Patients with
histologically proven lymphoma, who underwent both [18F]-FDG-PET/CT and whole-body
MRI (including T1- and diffusion-weighted [DWI] sequences) within seven days, and a sub-
sequent bone marrow biopsy, were retrospectively included. Three hybrid imaging combina-
tions were evaluated: (1) [18F]-FDG-PET/CT; (2) [18F]-FDG-PET/T1; and (3) [18F]-FDG-
PET/DWI. The presence of focal or diffuse bone marrow infiltration was assessed by two
rater teams. Sensitivity, specificity, and accuracy for the detection of overall, focal, and dif-
fuse bone marrow involvement were compared between the three hybrid imaging combina-
tions. Overall, lymphomatous bone marrow involvement was found in 16/60 patients (focal,
8; diffuse, 8). Overall sensitivity, specificity, and accuracy were 81.3%, 95.5%, and 91.7% for
[18F]-FDG-PET/CT; 81.3%, 97.7%, and 93.3% for [18F]-FDG-PET/T1; and 81.3%, 95.5%,
and 91.7% for [18F]-FDG-PET/DWI. No statistically significant differences between the three
imaging combinations were observed, based on overall bone marrow involvement, focal
involvement, or diffuse involvement. The sensitivity of all three imaging combinations for
detecting diffuse bone marrow involvement was only moderate (62.5% for all three combina-
tions). Although the combination of [18F]-FDG-PET and T1-weighted MRI generally showed
the best diagnostic performance for the detection of bone marrow involvement in lymphoma,
it was not significantly superior to the two other hybrid imaging combinations. Since the sen-
sitivity of all imaging combinations for the detection of diffuse bone marrow involvement was
only moderate, bone marrow biopsy cannot be replaced by imaging as yet.
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Introduction
Multifocal or diffuse bone marrow involvement in lymphoma patients is a criterion for Ann
Arbor stage IV disease, and often has a considerable effect on therapy and prognosis [1]. Bone
marrow involvement is found in about 5–15% of patients with Hodgkin lymphoma (HL), and
in 20–40% of patients with Non-Hodgkin lymphoma (NHL), depending on the histological
subtype [2, 3]. Currently, 2-F-18-fluoro-2-deoxy-D-glucose-positron emission tomography/
computed tomography ([18F]-FDG-PET/CT) is the recommended imagingmethod for initial
staging and follow-up for the majority of lymphomas. Nevertheless, detection of bone marrow
involvement—particularly diffusemarrow infiltration—on [18F]-FDG-PET/CTdepends
heavily on the histologic lymphoma subtype. Specifically, indolent lymphomas, such as follicu-
lar lymphomas are challenging in that regard. Thus, unilateral (or, more rarely, bilateral) blind
bonemarrow trephine biopsy (BMB) of the iliac crest is still a standard procedure in all lym-
phomas except HL [1]. However, BMB is associatedwith the small but recognized risks of hem-
orrhage or fracture, and is frequently regarded as painful, when performedwithout conscious
sedation. Another limitation of this biopsy technique is the lack of image guidance, which can
lead to false-negative results in cases of focal bone involvement. However, there are currently
no guidelines, or sufficient data, that support the notion that use of image-guidedbiopsy, rather
than standard iliac crest biopsy, has a clinically relevant effect on staging, or improves patient
survival.
Whole-bodymagnetic resonance imaging (MRI) has shown promise as an alternative to
[18F]-FDG-PET/CT for lymphoma staging, and possibly also for follow-up, particularly when
diffusion-weighted imaging (DWI) sequences are included in the protocol [4–7]. DWI is a
functionalMRI technique that relies on the restriction of water movement in hypercellular
tumors due to extracellular space narrowing, and thus, enables an indirect assessment of cell
density. While DWI has been reported to increase the accuracy of MRI for the assessment of
bonemetastases from different tumors [8, 9], its value for the detection of bonemarrow infil-
tration in lymphoma is still controversial [10, 11].
The aim of the present study was, therefore, to determine the value of different combina-
tions of [18F]-FDG-PETwith morphological or functional CT- or MRI-based imaging tech-
niques, which may be combined in the form of hybrid imaging (i.e., PET/CT or PET/MRI), for
the detection of bonemarrow involvement in lymphoma. In this context, the question of
whether [18F]-FDG-PET/MRImight be superior to [18F]-FDG-PET/CT for the assessment of
diffuse bone marrow involvement received special attention.
Materials and Methods
Patients and Design
This retrospective single-center study of patients was approved by the local Institutional
ReviewBoard (Medical University Vienna) according to the Declaration of Helsinki. Informed
consent was waived.A database search was performed to identify all patients with (1) histologi-
cally proven lymphoma and subtype classification according to the current classification of the
World Health Organization (WHO) for hematologic and lymphoid malignancies, and who
had (2) undergone both pre-therapeutic [18F]-FDG-PET/CTand additional whole-bodyMRI
with DWI at 3.0 Tesla (in the course of previous, prospective studies, or for routine purposes),
and in whom (3) a pre-therapeutic bone marrow biopsy and histological work-up had been
performed in-house, by a reference pathologist specializing in hematological malignancies. The
maximum allowed time interval between the first of the two imaging examinations (PET/CT
or MRI) and bone marrow biopsy was one month. Exclusion criteria were a record of
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therapeutic interventions between [18F]-FDG-PET/CTand whole-bodyMRI, the presence of
severeMRI artifacts, or an incomplete MR examination.
Imaging
Whole-body [18F]-FDG-PET/CTwas performed for routine diagnostic purposes using a
64-row multi-detector PET/CT scanner (Biograph TruePoint64; Siemens, Erlangen, GER).
Glucose levels were measured before the examination, with a cut-off limit of 8 mmol/L (150
mg/dL). Imaging was performed 50–60 min following the intravenous administration of 300
MBq of [18F]-FDG. First, CT was performed after an intravenous injection of 100 mL of a
tri-iodinated, non-ionic contrast medium (Iomeron 300; Bracco, Milan, ITA) at a rate of 2
mL/s, followed by a 50-mL saline flush. The following acquisition parameters were used: a
tube voltage of 230 kV; a tube current of 120 mA; a collimation of 64 × 0.6 mm; a slice thick-
ness of 3 mm with 2-mm increments; and a matrix of 512×512. CT was acquired in a breath-
hold during (non-forced) expiration. Afterward, without changing the patient’s position, a
whole-body PET acquisition was performed over five to six bed positions with 3 min/bed
position. PET images were reconstructed using the iterative TrueX algorithm (Siemens,
Erlangen, Germany), which incorporates a specific correction for the point-spread function
in addition to commonly used correction factors. Four iterations per 21 subsets were used,
with a matrix size of 168×168 and a transaxial field of view of 605 mm (pixel size 3.6 mm),
and a section thickness of 5 mm. The attenuation correction was based on the CT maps. CT
and PET data were co-registered, and image fusion was performed to generate color-coded
images.
Whole-bodyMRI was performed on a 3Tesla MR scanner (TrioTim; Siemens, Erlangen,
Germany). The study protocol included an established, commercially available, single-shot
echo planar imaging (EPI)-based spectral adiabatic inversion recovery DWI sequence and a
T1-weighted turbo spin-echo, or (in case of breathing difficulties) a fast gradient-echo
(FLASH, fast low angle short) sequence. The DWI sequence was performedwith b-values of
50 and 1000, a repetition time (TR)/ echo time (TE) of 5100/73ms, five averages, 86 phase
encoding steps, a 192x115 matrix, and a slice thickness of 5mm with no gap. Axial images of
the head and neck, chest, abdomen, and pelvis were sequentially obtained using a whole-body,
phased-array surface coil for signal reception. Images were acquired during free breathing
with a scan time of 4 minutes and 5 seconds per body region, except for the lower neck and
chest, where respiratory gating was used with a prolonged scan time of 5 minutes and 2 sec-
onds. Depending on the patients’ body height, four to five image stacks were necessary, with a
total scan time between 20 and 25 min. Apparent diffusion coefficient (ADC)maps were gen-
erated automatically by the operational software supplied by the scanner manufacturer of the
above-mentionedMR scanner. Axial T1-weighted sequences were obtained for better ana-
tomical/morphological correlation, and to generate fused, color-codedDWI-MRI images. The
T1-weighted, turbo spin-echo sequence was performedwith a scan time of 1 minute 5 sec-
onds; or alternatively, the fast T1-weighted gradient-echo sequence, with a scan time of 43
seconds.
Bone marrow biopsy
Bonemarrow biopsy (BMB) of the left iliac crest was performed by an experiencedboard-certi-
fied hematologist, without any form of imaging guidance, and before any form of systemic
therapy was applied. A board-certifiedreference pathologist, who was blinded to all imaging
data and results, analyzed all tissue samples.
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Image analysis
The following three imaging combinations were evaluated for the presence of bonemarrow
involvement in lymphoma: (1) [18F]-FDG-PET/CT; (2) [18F]-FDG-PET+ T1-weightedMRI
([18F]-FDG-PET/T1); and (3) [18F]-FDG-PET+ DWI ([18F]-FDG-PET/DWI).
For [18F]-FDG-PET/CT, focal bone marrow involvement was defined as the presence of
one or more well-circumscribedareas of abnormal FDG uptake that was higher than the
uptake in the liver, regardless of the appearance on CT. Similarly, diffuse bonemarrow involve-
ment in PET/CT was defined as visually elevated, diffuse FDG uptake (i.e., with ill-definedbor-
ders or confluent, patchy abnormal uptake), which was higher than the uptake of the liver,
regardless of the appearance on CT.
For [18F]-FDG-PET/T1, the presence of one or more well-circumscribedfocal areas, or a
diffuse area of abnormal FDG uptake that was higher than the uptake in the liver, was rated as
positive, provided that there were also corresponding ill-definedhypointense signal changes on
T1 (lower signal than that of normal vertebral discs).
For [18F]-FDG-PET/DWI, the presence of one or more well-circumscribed focal areas, or a
diffuse area of abnormal FDG uptake that was higher than the uptake in the liver, was rated as
positive, provided that there was a corresponding focal or diffuse area of diffusion restriction
(high signal intensity on the b-1000 image and corresponding low signal intensity on the co-
registered ADCmap). A focal area of diffusion restrictionwas also rated as positive in the
absence of an increased FDG uptake.
All imaging combinations were reviewed on a Syngo workstation, using the dedicated
“TrueD” software module (Siemens, Erlangen, Germany). Image interpretation was performed
by two independent teams, which consisted of a board-certifiedradiologist (R.N.,M.M.) and a
board-certifiednuclear medicine physician (G.K., A.S.) who specialized in oncological imaging.
Readers were aware of the patient diagnosis of lymphoma, but were blinded to the histologic
subtype. Imaging combinations were assessed in three reading sessions (first, [18F]-FDG-PET/
CT; second, [18F]-FDG-PET/T1; third, [18F]-FDG-PET/DWI), with a time interval of two
weeks between the reading sessions. Patient order was randomly assigned in each reading ses-
sion for each reading team.
Standard of reference
The consensus rating by an expert team, consisting of a senior radiologist, a senior nuclear
medicine physician, and a senior pathologist, who had access to all imaging studies (including,
if available, follow-up imaging and the results of BMB), was used as standard of reference.
Focal bone marrow involvement was regarded as present when either the BMB result was posi-
tive, or when a focal FDG uptake, higher than that in the normal liver parenchyma, was present
on the pre-therapeutic [18F]-FDG-PET/CT, and subsequently disappeared or was clearly
lower (by at least 25%), on the follow-up [18F]-FDG-PET/CT. Diffuse bonemarrow involve-
ment was considered positive only in case of a positive BMB result, since diffuse FDG-uptake
in PET may also be attributable to benign causes, such as inflammatory changes or elevated
metabolism of hematopoietic tissue [12, 13].
Statistical considerations
Statistical planning and analysis were performed by a statistician (M.W.), using the SPSS 22.0
software package for MicrosoftWindows, (SPSS Inc., Chicago, lL, USA). Sensitivity, specificity,
negative and positive predictive values, and accuracy, with their corresponding 95% confidence
intervals for the detection of bone marrow involvement were calculated separately for [18F]-
FDG-PET/CT, [18F]-FDG-PET/T1, and [18F]-FDG-PET/DWI, and independently for each of
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the two rater teams. Data analysis was also separately performed for overall, focal, and diffuse
bonemarrow involvement. Sensitivity, specificity, negative and positive predictive value, and
accuracywere also calculated for BMB. McNemar tests were used for pairwise comparison of
accuracies of the three imaging combinations, and kappa (κ) coefficientswere used to assess
interobserver agreement. The specified level of significancewas 5% for all tests.
Results
Patients
Overall, 72 patients matched the inclusion criteria. Of these, six patients were excluded because
of an incomplete MR examination, or artifacts; three were excluded because PET/CT had not
been performed in-house; and three patients were excluded because the time interval between
[18F]-FDG-PET/CT, MRI and BMB exceeded one month. Thus, 60 patients (32 females and
28 males; mean age, 51.2±16.7 years; age range, 20–80 years) were available for further analysis.
Eighteen patients were diagnosedwith Hodgkin lymphoma (HL), 16 with diffuse large B-cell
lymphoma (DLBCL), 11 with follicular lymphoma (FL), six with extranodalmarginal zone B-
cell lymphoma of the mucosa-associated lymphoid tissue (MALT), four with mantle cell lym-
phoma (MCL), four with nodal marginal zone lymphoma (nMZL), and one with anaplastic
large cell lymphoma (ALCL) (Table 1).
Standard of reference and BMB
By consensus, bone marrow infiltration was considered present in 16/60 patients; 15/16 were
diagnosedwith an NHL, and one with an HL. Eight patients (sevenNHL [three DLBCL, three
FL, one MALT], one HL) showed focal bone marrow involvement, whereas the remaining
eight patients with NHL (four FL, threeMCL, one nMZL) showed diffuse bone marrow infil-
tration. Bone marrow biopsy was positive in 12/60 patients with a sensitivity, specificity, PPV,
NPV, and accuracy of 75%, 100%, 100%, 91.7%, and 86.7%, respectively. Examples are given in
Figs 1 and 2.
In patients with focal involvement, BMB was false-negative in 4/8 cases, with a sensitivity,
specificity, PPV, NPV, and accuracy of 50%, 100%, 100%, 91.7%, and 92.3%, respectively. Due
to the fact the BMB was mandatory for the diagnosis of diffuse bone marrow infiltration, BMB
was positive in 8/8 patients.
Table 1. Distribution of bone marrow involvement between the different lymphoma subtypes.
N = 60 Negative Focal Diffuse
HL 17 1 0
DLBCL 13 3 0
FL 4 3 4
nMZL 3 0 1
MALT 5 1 0
MCL 1 0 3
ALCL 1 0 0
HL, Hodgkin lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; nMZL, nodal
marginal zone lymphoma; MALT, extranodal marginal zone B-cell lymphoma of the mucosa-associated
lymphoid tissue; MCL, mantle cell lymphoma; ALCL, anaplastic large cell lymphoma
doi:10.1371/journal.pone.0164118.t001
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Fig 1. Focal bone marrow involvement. A 70-year-old female patient with histologically verified DLBCL and a focal bone marrow lesion
in the left humerus. There is a perfect match between [18F]-FDG-PET and the fused color-coded PET/CT images (a-c); DWI and the fused
color-coded [18F]-FDG-PET/DWI images (d-f); and [18F]-T1-weighted images and fused color-coded PET/T1 images (g-i), with regard to
the detection of the focal lesion in the humerus.
doi:10.1371/journal.pone.0164118.g001
Fig 2. Diffuse bone marrow involvement. A 46-year-old male patient with histologically verified MCL, and diffuse bone marrow
involvement proven by BMB and histology. There is a perfect match between [18F]-FDG-PET/CT and the fused color-coded PET/CT
images (a-c); DWI and the fused color-coded [18F]-FDG-PET/DWI images (d-f); and [18F]-T1-weighted images and fused color-coded
PET/T1 images (g-i), with regard to the detection of diffuse bone marrow involvement in the pelvic bones.
doi:10.1371/journal.pone.0164118.g002
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Performance of [18F]-FDG-PET/CT
Rater team 1 correctly evaluated bone marrow status on [18F]-FDG-PET/CT in 51/60 patients
(85%), of whom 11 patients (six patients with focal, and five with diffuse affection) showed
bonemarrow involvement. Of the four false-positive patients, three had diffusely increased
bonemarrow uptake, but had a negative BMB. Five patients were false-negative (two patients
with focal, and three with diffusemarrow affection).Overall, [18F]-FDG-PET/CThad a sensi-
tivity, specificity, and accuracy of 68.8%, 90.9%, and 85.0%, respectively.
Rater team 2 correctly evaluated bonemarrow status on [18F]-FDG-PET/CT in 55/60
patients (91.7%), whereas 13 patients were positive for bone marrow involvement (eight
patients with focal, and five with diffuse affection). Two false-positive-rated patients showed
diffusely increased bonemarrow uptake, but were negative on BMB. The remaining three
patients who were false-negative on [18F]-FDG-PET/CT showed a positive BMB result. Sensi-
tivity, specificity, and accuracy for PET/CT were 81.3%, 95.5%, and 91.7%, respectively (Tables
2–4).
Table 2. Overall performance of the different imaging combinations for the detection of bone marrow involvement in lymphoma.
N = 60 Sensitivity Specificity PPV NPV Accuracy Interrater κ
Rater 1
[18F]-FDG-PET/CT 0.69 (0.41–0.88) 0.91 (0.77–0.97) 0.73 (0.45–0.91) 0.89 (0.75–0.96) 0.85 (0.74–0.92) 0.67 (P<0.001)
[18F]-FDG-PET/T1 0.69 (0.42–0.88) 0.93 (0.8–0.98) 0.79 (0.49–0.94) 0.89 (0.76–0.96) 0.87 (0.76–0.93) 0.83 (P<0.001)
[18F]-FDG-PET/DWI 0.81 (0.54–0.95) 0.93 (0.8–0.98) 0.81 (0.54–0.95) 0.93 (0.80–0.98) 0.90 (0.80–0.95) 0.88 (P<0.001)
Rater 2
[18F]-FDG-PET/CT 0.81 (0.54–0.95) 0.96 (0.83–0.99) 0.87 (0.58–0.98) 0.93 (0.81–0.98) 0.92 (0.82–0.96) -
[18F]-FDG-PET/T1 0.81 (0.54–0.95) 0.98 (0.87–1) 0.93 (0.64–1) 0.94 (0.81–0.98) 0.93 (0.84–0.97) -
[18F]-FDG-PET/DWI 0.81 (0.54–0.95) 0.96 (0.83–0.99) 0.87 (0.58–0.98) 0.93 (0.81–0.98) 0.92 (0.82–0.96) -
BMB 0.75 (0.47–0.92) 1.0 (0.9–1) 1.0 (0.7–1) 0.92 (0.79–0.97) 0.87 (0.76–0.93) -
Values in parentheses represent 95% confidence intervals
PPV, positive predictive value; NPV, negative predictive value
doi:10.1371/journal.pone.0164118.t002
Table 3. Focal bone marrow involvement—diagnostic performance of the different imaging combinations.
N = 52 Sensitivity Specificity PPV NPV Accuracy Interrater κ
Rater 1
[18F]-FDG-PET/CT 0.75 (0.36–0.96) 0.91 (0.77–0.97) 0.60 (0.27–0.86) 0.95 (0.83–0.99) 0.89 (0.77–0.95) 0.76 (P<0.001)
[18F]-FDG-PET/T1 0.88 (0.47–0.99) 0.93 (0.8–0.98) 0.70 (0.35–0.92) 0.98 (0.86–1.0) 0.92 (0.82–0.97) 0.81 (P<0.001)
[18F]-FDG-PET/DWI 1.0 (0.60–1.0) 0.93 (0.8–0.98) 0.73 (0.39–0.93) 1.0 (0.89–1.0) 0.94 (0.84–0.98) 0.94 (P<0.001)
Rater 2
[18F]-FDG-PET/CT 1.0 (0.6–1) 0.96 (0.83–0.99) 0.80 (0.44–0.97) 1.0 (0.9–1.0) 0.96 (0.87–0.99) -
[18F]-FDG-PET/T1 1.0 (0.60–1.0) 0.98 (0.87–1.0) 0.89 (0.51–0.99) 1.0 (0.90–1.0) 0.98 (0.90–1.0) -
[18F]-FDG-PET/DWI 1.0 (0.6–1.0) 0.96 (0.83–0.99) 0.80 (0.44–0.97) 1.0 (0.90–1.0) 0.96 (0.87–0.99) -
BMB 0.5 (0.17–0.83) 1.0 (0.90–1.0) 1.0 (0.40–1.0) 0.92 (0.79–0.97) 0.92 (0.82–0.97) -
Values in parentheses represent 95% confidence intervals
PPV, positive predictive value; NPV, negative predictive value
doi:10.1371/journal.pone.0164118.t003
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Performance of [18F]-FDG-PET/T1
Rater team 1 correctly evaluated bone marrow status on [18F]-FDG-PET/T1 in 54/60 patients
(86.7%). Three patients were false-positive, all of whom had signs of diffusemarrow infiltra-
tion. All of the three false-negative patients had a positive BMB. Sensitivity, specificity, and
accuracy for [18F]-FDG-PET/T1were 68.8%, 93.2%, and 86.7%, respectively.
Rater team 2 also assessed bonemarrow status correctly in 56/60 patients (93.3%). Three
patients were false-negative, and the single false-positive patient again showed signs suggestive
of diffusemarrow infiltration at imaging. Thus, sensitivity, specificity, PPV, NPV, and accuracy
for [18F]-FDG-PET/T1were 100%, 97.7%, and 98.1%, respectively (Tables 2–4).
Performance of [18F]-FDG-PET/DWI
Rater team 1 correctly evaluated bone marrow status on PET/DWI in 54/60 patients (90%).
Three patients were false-positive, all of whom had with signs of diffusemarrow infiltration.
All of the three false-negative patients had a positive BMB. Sensitivity, specificity, and accuracy
for [18F]-FDG-PET/DWIwere 81.3%, 93.2%, and 90.0%, respectively.
Rater team 2 also assessed bonemarrow status correctly in 55/60 patients (91.7%). Three
patients were false-negative, and the two false-positive patients again showed signs suggestive
of diffusemarrow infiltration at imaging. Thus, sensitivity, specificity, and accuracy for [18F]-
FDG-PET/DWIwere 81.3%, 95.5%, and 91.7%, respectively (Tables 2–4).
Comparison of accuracies and interrater agreement
McNemar tests did not reveal statistically significant differences between any of the three imag-
ing combinations in terms of accuracy (P>0.05). The kappa values between the two rater
teams ranged from 0.67 to 1.0 (overall), and from 0.76 to 1.0 for focal involvement. However,
for diffuse infiltration, there was only a moderate interrater agreement, with kappa values
between 0.56 and 0.74 (Tables 2–4).
Discussion
Our study is, to our knowledge, the first that specifically compares three hybrid imaging com-
binations—[18F]-FDG-PET/CT, [18F]-FDG-PET/T1, and [18F]-FDG-PET/DWI—for the
detection of bone marrow involvement in lymphoma patients. This topic is of relevance due to
the fact that PET/MRI is an emerging technique whose diagnostic value is yet to be established,
Table 4. Diffuse bone marrow involvement—diagnostic performance of the different imaging combinations.
N = 52 Sensitivity Specificity PPV NPV Accuracy Interrater κ
Rater 1
[18F]-FDG-PET/CT 0.63 (0.26–0.90) 0.91 (0.77–0.97) 0.56 (0.23–0.85) 0.93 (0.80–0.98) 0.87 (0.75–0.93) 0.56 (P<0.001)
[18F]-FDG-PET/T1 0.50 (0.17–0.83) 0.93 (0.80–0.98) 0.57 (0.20–0.88) 0.91 (0.78–0.97) 0.87 (0.75–0.93) 0.74 (P<0.001)
[18F]-FDG-PET/DWI 0.63 (0.26–0.90) 0.93 (0.80–0.98) 0.63 (0.26–0.90) 0.93 (0.80–0.98) 0.89 (0.77–0.95) 0.77 (P<0.001)
Rater 2
[18F]-FDG-PET/CT 0.63 (0.26–0.90) 0.96 (0.83–0.99) 0.71 (0.30–0.95) 0.93 (0.81–0.98) 0.90 (0.79–0.96) -
[18F]-FDG-PET/T1 0.63 (0.26–0.90) 0.98 (0.87–1.0) 0.83 (0.37–0.99) 0.94 (0.81–98) 0.92 (0.82–0.97) -
[18F]-FDG-PET/DWI 0.63 (0.26–0.90) 0.96 (0.83–0.99) 0.71 (0.30–0.95) 0.93 (0.81–0.98) 0.90 (0.79–0.96) -
BMB 1.0 (0.60–1.0) 1.0 (0.90–1.0) 1.0 (0.60–1.0) 1.0 (0.90–1.0) 1.0 (0.93–1.0) -
Values in parentheses represent 95% confidence intervals
PPV, positive predictive value; NPV, negative predictive value
doi:10.1371/journal.pone.0164118.t004
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and due to the role of bone marrow involvement in the Ann Arbor staging system, i.e., assign-
ment of patients to stage IV [14]. Our study results indicate that [18F]-FDG-PET/MR—regard-
less of whether [18F]-FDG-PET is combined with T1-weightedMRI, or with DWI—provides a
level of diagnostic performance similar to that of the current hybrid imaging standard tech-
nique, [18F]-FDG-PET/CT.
Nevertheless, despite a lack of statistically significant difference, between the three imaging
combinations, the combinations of [18F]-FDG-PETwith T1-weightedMRI, and DWI, were
slightly superior to [18F]-FDG-PET/CT, in terms of accuracy (Tables 2–4). This finding is of
interest due to the availability of PET/MR scanners that offer combinations of both PET and
MRI in a single examination. However, our results do not justify, or even suggest, the replace-
ment of [18F]-FDG-PET/CTby [18F]-FDG-PET/MRIbased on its performance in bone mar-
row assessment, particularly in view of the considerably higher costs associated with PET/MR.
In addition, the most frequently usedmethod of PET attenuation correction for PET/MRI typi-
cally relies on two-point VIBE Dixon T1-weighted sequences, where cortical bone is assigned
to the soft tissues, which, in turn, leads to a systematic underestimation of standardized uptake
values [15]. Only in young patients, for which exposure to ionizing radiation should be as low
as possible in order to minimize the risk of secondary radiation-induced cancer, can [18F]-
FDG-PET/MRI be considered a better choice than PET/CT, since our results, while unable to
demonstrate a superiority, also did not demonstrate an inferiority, with regard to bonemarrow
status assessment, compared to [18F]-FDG-PET/CT.
As expected, due to the presence of patients with focal bone marrow involvement in our
study population, unilateral iliac crest bone marrow biopsy (which is the current diagnostic
standard for bonemarrow evaluation in lymphoma patients), showed a clearly lower sensitivity
than each of the three imaging combinations. However, for the assessment of diffusemarrow
infiltration, none of the three imaging combinations was able to provide a diagnostic perfor-
mance that was comparable to that of bonemarrow biopsy. These findings provide further
proof that imagingmay have a complementary role in such patients, and could thus be useful
chiefly for guiding biopsies. For the [18F]-FDG-PET-based combinations, one major factor
that may lead to false-positive findings is the fact that a diffuse FDG tracer uptake is frequently
seen in hematopoietic tissue, or is attributable to reactive / inflammatorymarrow changes [12,
13]; here, the histologic subtype should probably be taken into account, because it is well-
known that diffuse bone marrow infiltration is mainly found in NHL, particularly in the indo-
lent subtypes. This was also evident when looking at our own data, where a diffusemarrow
infiltration was observed exclusively in indolent NHL. The latter may also be responsible for
our false-negative [18F]-FDG-PET findings, because indolent NHL frequently show a rather
low glycolytic activity, compared to the aggressive subtypes [16]. Here, dual or delayed time-
point [18F]-FDG-PET, which has shown improved visualization of MALT lymphomas in a
previous study [17], may possibly be helpful.
The question of whether DWI is a vital part of whole-bodyMRI protocols in the context of
lymphomatous bonemarrow involvement has previously been investigated by Kwee et al., who
found no difference in sensitivity betweenwhole-bodyMRI with, and whole-bodyMRI with-
out, DWI [10]. The sensitivities of MRI with/without DWI were generally unsatisfactory in
their study, for which [18F]-FDG-PET/CTwas not available, but which used BMB as the only
standard of reference. In view of the latter, the authors pointed out that the actual sensitivity of
MRI with/without DWI may be higher, due to focal lesions missed by standard iliac crest
biopsy. Ribrag et al. compared the diagnostic performance of BMB, whole-bodyMRI, and
[18F]-FDG-PET/CT for bone marrow infiltration in 43 patients with aggressive lymphomas,
and observed good agreement betweenMRI and [18F]-FDG-PET/CT, with patient-based sen-
sitivities of 100% and 100%, respectively, and lesion-based sensitivities of 83% and 96%,
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respectively; both imaging techniques also identifiedmore patients with bonemarrow involve-
ment than BMB [18]. However, these authors used a STIR and a T1-weightedMR sequence,
but no DWI, and they did not differentiate between focal and diffuse involvement by imaging.
Adams et al. also compared whole-bodyMRI to [18F]-FDG-PET for the detection of bone
marrow involvement in 116 patients with aggressive and indolent lymphomas, using BMB as
the reference standard [19]. Again, in their study, there was no significant difference in terms
of marrow involvement detection between the two imagingmodalities; while they used DWI as
part of their MRI protocol, they did not evaluate its role and potential benefits. In our own
study, which combined [18F]-FDG-PETwith DWI, and with T1-weightedMRI, no clear bene-
fit arose from the use of DWI, which suggests that, for bone marrow assessment on PET/MRI,
DWI may be omitted.
Our study had several limitations. First, due to our strict inclusion criteria (e.g., regarding
the maximum time interval between imaging and bonemarrow biopsy), the number of patients
with histological proof of bonemarrow involvement was limited. Due to the retrospective char-
acter of our study, patients with focal bone marrow involvement that was missed by biopsy
could not be assigned to guided biopsy to obtain definitive proof of lymphomatous involve-
ment; however, it is highly unlikely that lesions that met our non-histology-basedcriteria for
bonemarrow involvement—i.e., a therapy-induced reduction of FDG uptake—were actually
benign. Second, [18F]-FDG-PET and the twoMR sequences (T1-weighted and DWI) were not
obtained on an integrated hybrid PET/MRI scanner, but on two separate devices, which may
affect conclusions regarding the comparative performances of PET/CT and PET/MRI, due to
the above-mentioned differences in terms of attenuation correction for PET. Nevertheless, the
CT-based attenuation correction used in our study is the current standard technique for PET,
and is considered to be more reliable than MRI-based attenuation correction. Finally, subgroup
analyses between the different NHL lymphoma types, with regard to sensitivity, specificity, and
accuracywere not possible, due to the small number of patients in each group.
In conclusion, the results of our study indicate that, compared to [18F]-FDG-PET/CT, the
use of [18F]-FDG-PET/MRImay provide only a minor degree of improvement, with regard to
the assessment of bone marrow status in patients with lymphoma, but not a statistically signifi-
cant advantage. Notably, in the context of [18F]-FDG-PET/MRI,DWI does not provide an
advantage, compared to T1-weightedMRI, for the assessment of bone marrow involvement.
Since the sensitivity of [18F]-FDG-PET/CTand the two PET/MRI combinations was only
moderate for the detection of diffuse bone marrow involvement, bone marrow biopsy cannot
be replaced by imaging as yet.
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